NPS+(¹Ì±¹) : °Ç¼±¼º °üÀý¿°
NPS+ (US) - Psoriatic Arthritis
»óǰÄÚµå : 1749306
¸®¼­Ä¡»ç : FirstWord Group
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 8,000 £Ü 11,619,000
Multi User License (PDF) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹Ì±¹ÀÇ ·ù¸¶Æ¼½º Àü¹®ÀǵéÀº °Ç¼±¼º °üÀý¿° Ä¡·á¿¡ ÀÖ¾î ´Ù¾çÇÑ ¼±ÅÃÁö¸¦ °¡Áö°í ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ ÀϺΠġ·áÁ¦´Â ´Ù¸¥ Ä¡·áÁ¦º¸´Ù ´õ ³ôÀº ·Î¿­Æ¼¿Í ¸¸Á·µµ¸¦ ¾ò°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ±× ÀÌÀ¯´Â ¹«¾ùÀϱî¿ä? ÀÇ»çµéÀÇ ¼±ÅÃÀ» Á¿ìÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀ̸ç, ÁÖ¿ä ºê·£µå´Â °æÀï»ç ´ëºñ ¾î¶»°Ô ´Ù¸¥°¡? ÀÌ º¸°í¼­¿¡¼­´Â ¹Ì±¹ ³» ÁÖ¿ä °Ç¼±¼º °üÀý¿° Ä¡·áÁ¦¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä Áú¹®:

ÁÖ¿ä ºê·£µå:

  • Humira (adalimumab)
  • Remicade (infliximab)
  • Cimzia (certolizumab pegol)
  • Bimzelx (bimekizumab)
  • Cosentyx (secukinumab)
  • Simponi (golimumab)
  • Enbrel (etanercept)
  • Rinvoq (upadacitinib)
  • Xeljanz (tofacitinib)
  • Stelara (ustekinumab)
  • Skyrizi (risankizumab)
  • Tremfya (guselkumab)
  • Taltz (ixekizumab)

Á¶»ç ¹æ¹ý:

FirstView º¸°í¼­´Â 300¸¸ ¸í ÀÌ»óÀÇ µî·Ï Àǻ縦 º¸À¯ÇÑ ¼¼°è ÃÖ´ë ±Ô¸ðÀÇ ÀÇ»ç µ¥ÀÌÅͺ£À̽ºÀÎ LiMATMÀ» ÅëÇØ ¼±º°µÈ ÀÇ»çµéÀ» ´ë»óÀ¸·Î ÇÑ Á¤·®Àû ¼³¹®Á¶»ç¸¦ ±â¹ÝÀ¸·Î ÀÛ¼ºµÇ¾ú½À´Ï´Ù. ¸ðµç ÀÇ»ç´Â ¾ö°ÝÇÑ ¼±º° ±âÁØ¿¡ µû¶ó ½ÅÁßÇÏ°Ô ¼±Á¤µÇ¾úÀ¸¸ç, ¼öÁýµÈ ÀλçÀÌÆ®°¡ ÇöÀå Àϼ±¿¡¼­ Ȱµ¿ÇÏ´Â ÀÇ·á Àü¹®°¡µéÀÇ ½ÇÁ¦ Àǰ߰ú °æÇèÀ» Á¤È®ÇÏ°Ô ¹Ý¿µÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾î °ü·Ã¼º°ú ½Å·Ú¼ºÀÌ ³ô½À´Ï´Ù. Á¶»ç °á°ú´Â Á÷°üÀûÀ¸·Î ÀÌÇØÇϱ⠽¬¿î ±×·¡ÇÁ¿Í Â÷Æ®·Î Á¦°øµÇ¾î ºü¸¥ ÀÌÇØ¿Í ºÐ¼®ÀÌ °¡´ÉÇϸç, LiMAÀÇ ±¤¹üÀ§ÇÑ µµ´Þ ¹üÀ§¿Í Á¤È®¼ºÀ» Ȱ¿ëÇÏ¿© FirstView º¸°í¼­´Â µ¥ÀÌÅÍ ±â¹Ý ÀλçÀÌÆ®¸¦ Á¦°øÇÔÀ¸·Î½á ±Þº¯ÇÏ´Â ÇコÄÉ¾î ½ÃÀå¿¡¼­ Àü·«Àû ÀÇ»ç°áÁ¤¿¡ µµ¿òÀ» ÁÝ´Ï´Ù.

º» º¸°í¼­ÀÇ Æ¯Â¡:

FirstWordÀÇ º¸°í¼­´Â Á¦¾à »ê¾÷À» Àü¹®À¸·Î ÇÏ´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾÷°è ¸®´õ·Î¼­ ¹ÙÀÌ¿ÀÁ¦¾à Àü¹®°¡¿Í ÀÇ»ç°áÁ¤±ÇÀÚ¸¦ À§ÇÑ ±íÀÌ ÀÖ°í ½Ç¿ëÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ¾÷°è Àü¹Ý¿¡ ´ëÇÑ Ç³ºÎÇÑ Áö½ÄÀ» ¹ÙÅÁÀ¸·Î »õ·Î¿î Æ®·»µå¸¦ ÆÄ¾ÇÇÏ°í º¹ÀâÇÑ °úÁ¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇÒ ¼ö ÀÖµµ·Ï °ü·Ã¼º ³ô°í °¡Ä¡ ÀÖ´Â Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â ±¤¹üÀ§ÇÑ ¸®¼­Ä¡¿Í ÁÖ¿ä Àü¹®°¡ ¹× KOL(Key Opinion Leader)ÀÇ µ¶¸³ÀûÀ̰í Á߸³ÀûÀÎ ºÐ¼®À» ÅëÇØ ³ôÀº Á¤È®¼º°ú ½Å·Ú¼ºÀ» º¸ÀåÇÕ´Ï´Ù. FirstWord Reports´Â 40°³ ÀÌ»óÀÇ Áúȯ ºÐ¾ß¿¡ ´ëÇÑ ÀÇ»çµéÀÇ ÅëÂû·Â(KOLÀÇ °ßÇØ ¹× Á¤·®Àû Á¶»ç °á°ú)°ú ÇÔ²² 40°³ ÀÌ»óÀÇ Áúȯ¿¡ ´ëÇÑ ÀÇ»çµéÀÇ ÅëÂû·Â(KOLÀÇ °ßÇØ ¹× Á¤·®Àû Á¶»ç °á°ú), ÀÇ·á°è À̽´¿¡ ´ëÇÑ ºÐ¼® ¹× ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ¸ÞµðÄà ¾îÆä¾î, µðÁöÅÐ Çコ, ¿µ¾÷ ¹× ¸¶ÄÉÆÃ, ½ÃÀå Á¢±Ù¼º µî ´Ù¾çÇÑ ºÐ¾ßÀÇ ¾÷°è Àü¹®°¡µéÀÇ Àǰߵµ ÇÔ²² ´Ù·ç°í ÀÖ½À´Ï´Ù.

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

There are various options available to US rheumatologists treating psoriatic arthritis. Clearly, some of these options achieve greater levels of loyalty and satisfaction than others, but why? What are the key factors driving physician choice, and how does each of the leading brands compare to its competitors? Gain insights into leading psoriatic arthritis therapies in the US.

Key Questions Answered:

Key Brands:

  • Humira (adalimumab)
  • Remicade (infliximab)
  • Cimzia (certolizumab pegol)
  • Bimzelx (bimekizumab)
  • Cosentyx (secukinumab)
  • Simponi (golimumab)
  • Enbrel (etanercept)
  • Rinvoq (upadacitinib)
  • Xeljanz (tofacitinib)
  • Stelara (ustekinumab)
  • Skyrizi (risankizumab)
  • Tremfya (guselkumab)
  • Taltz (ixekizumab)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â